Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib plus pembrolizumab versus pembrolizumab plus pemetrexed and platinum for first-line KRAS G12C-mutated non-squamous NSCLC
2024-518365-10-00Phase 3Suspended
- Sponsor
- Roche
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Divarasib + pembrolizumab with Pembrolizumab + pemetrexed + carboplatin or cisplatin (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Oct 2025; status: suspended.
02
Drugs
divarasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518365-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518365-10-00.